WHO ICTRP trial
Serum Amyloid A as a prognostic marker for disease severity and mortality in…
NL-OMON51218 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON51218 |
|---|---|
| Public title | Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19 |
| Scientific title | Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19 - SAVID |
| Primary sponsor | Franciscus Gasthuis & Vlietland |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | corona COVID-19 SAR-COV-2;10047438;corona;COVID-19;SAR-COV-2 |
| Interventions | ;biomarker;COVID-19;prognostic;serum amyloid A |
| Registration date | Jul 29, 2021 |
| Target size | 350 |
| Secondary IDs | NL76080.100.20;NL9082 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: